Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2011-08-16
2011-08-16
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S009100, C424S009200, C424S200100, C424S201100, C424S208100, C424S234100, C424S093400, C424S248100, C435S041000, C435S069100, C435S069300, C435S071100
Reexamination Certificate
active
07998471
ABSTRACT:
Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided areMycobacterium smegmatisexpressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in a mammal against HIV-1 and a malarial pathogen. Also provided are methods of inducing an immune response in a mammal against HIV-1. The methods comprise infecting the mammal with any of the above-described mycobacteria.
REFERENCES:
patent: 5504005 (1996-04-01), Bloom et al.
patent: 5591632 (1997-01-01), O'Donnell et al.
patent: 5736367 (1998-04-01), Haun et al.
patent: 5773267 (1998-06-01), Jacobs et al.
patent: 5776465 (1998-07-01), O'Donnell et al.
patent: 5830475 (1998-11-01), Aldovini et al.
patent: 6074866 (2000-06-01), Escuyer et al.
patent: 6235518 (2001-05-01), Gicquel et al.
patent: 6372478 (2002-04-01), Bloom et al.
patent: 6423545 (2002-07-01), Pavelka, Jr. et al.
patent: 6472213 (2002-10-01), Escuyer et al.
Chujoh, Y., et al. Vaccine, vol. 20, pp. 797-804, 2002.
Zheng, C., et al. Parasitology International, vol. 51, pp. 1-7, 2002.
Gallo. “The End or the Beginning of the Drive to an HIV-Preventive Vaccine: a View from Over 20 years.” Lancet 2005, vol. 366, pp. 1894-1898.
Gilbert et al. “HIV-1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy Among HIV-1-Infected Subjects in a Trial of the Efficacy of Recombinant glycoprotein 120 Vaccine.” The Journal of Infectious Diseases 2005, vol. 192, pp. 974-983.
The Search Report for PCT Application No. PCT/US2006/000790, dated May 8, 2006.
The Written Opinion of the International Searching Authority for PCT Application No. PCT/US2006/000790, dated May 11, 2006.
The International Preliminary Report on Patentability for PCT Application No. PCT/US2006/000790, dated May 11, 2006.
Cayabyab Mark
Haynes Barton F.
Hovav Avi-Hai
Jacobs, Jr. William R.
Letvin Norman L.
Albert Einstein College of Medicine of Yeshiva University
Amster Rothstein & Ebenstein LLP
Beth Israel Deaconess Medical Center Inc.
Duke University
Swartz Rodney P.
LandOfFree
Mycobacteria expressing HIV-1 and malaria antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mycobacteria expressing HIV-1 and malaria antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mycobacteria expressing HIV-1 and malaria antigens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2757448